Key Takeaways:
(Bloomberg) -- Medical device maker Dexcom Inc. will add two independent directors to its board in an agreement with activist investor Elliott Investment Management, a move that sent shares up about 6% in after-hours trading.
"We also see a clear path to significant margin expansion, underpinning one of the most compelling earnings growth profiles in MedTech," Marc Steinberg, partner at Elliott, said in a statement.
The San Diego-based company said it is working with Elliott to identify the new directors, who will have medical technology and operations experience. As part of the deal, Dexcom's Technology Committee will be renamed the Operations and Innovation Committee and will have an expanded mandate to oversee operations and quality.
The agreement puts shareholder returns in focus just as the company accelerates its product roadmap. The deal was announced ahead of Dexcom's Investor Day, where the company also unveiled its next-generation G8 continuous glucose monitor (CGM), which it plans to submit for FDA review next year.
The new G8 device features a 50% smaller form factor than the current G7 model and uses a new silicon chip and algorithm that adapts to a person's body over time, the company said. Dexcom is targeting a commercial launch for the G8 in late 2027 or early 2028, depending on the timing of regulatory review. The company also said it expects a Medicare coverage decision for its current-generation monitors by the end of this year.
The agreement with Elliott signals a heightened focus on improving operational efficiency and shareholder returns alongside the company's innovation pipeline. Investors will watch for the appointment of the new directors and the G8's FDA submission as the next key developments for the glucose monitor maker.
This article is for informational purposes only and does not constitute investment advice.
